Giuseppe Fusai, Parveen Dhaliwal, Nancy Rolando, Caroline Anne Sabin, David Patch, Brian Ritchie Davidson, Andrew Kenneth Burroughs, Keith Rolles – 1 September 2006 – Predictive factors for intrahepatic cholestasis after orthotopic liver transplantation (OLT) have not yet been established. We sought to identify the incidence and risk factors associated with prolonged severe intrahepatic cholestasis (PSIC) after OLT. We assessed 428 consecutive patients undergoing their first OLT.

George N. Ioannou – 1 September 2006 – This study aimed to develop and validate a comprehensive model that predicts survival after liver transplantation based on pretransplant donor and recipient characteristics. Complete data were available from the United Network for Organ Sharing for 20,301 persons who underwent liver transplantation in the United States between 1994 and 2003. Proportional‐hazards regression was used to identify the donor and recipient characteristics that best predicted survival and incorporate these characteristics in a multivariate model.

Tilak U. Shah, Richard C. Semelka, Vasilis Voultsinos, Jorge Elias Jr., Ersan Altun, Ertan Pamuklar, Zeynep Firat, David A. Gerber, Jeffrey Fair, Mark W. Russo – 1 September 2006 – The detection of main portal vein thrombosis (PVT) on preoperative imaging of liver transplant candidates has important technical implications for the transplantation procedure. Data are scarce regarding the accuracy of magnetic resonance imaging (MRI) at detecting PVT. The aim of our study was to compare preoperative findings of the portal vein on MRI to operative findings at liver transplantation.

Stuart A. McCluskey, Keyvan Karkouti, Duminda N. Wijeysundera, Karen Kakizawa, Mohammed Ghannam, Ahmed Hamdy, David Grant, Gary Levy – 1 September 2006 – Massive blood transfusion (MBT) remains a serious and common occurrence in liver transplantation surgery. This retrospective cohort study was undertaken to identify preoperative predictors of MBT and to develop a risk index for MBT in liver transplantation. Data were retrospectively collected on all liver transplantations carried out at a single institution between January 1998 and March 2004.

Patrizia Farci – 29 August 2006

Nicholas F. LaRusso, Benjamin L. Shneider, Dennis Black, Gregory J. Gores, Stephen P. James, Edward Doo, Jay H. Hoofnagle – 29 August 2006 – Primary sclerosing cholangitis (PSC) is a rare but important liver disease that leads to cirrhosis and need for liver transplantation in a high proportion of cases. The disease occurs in approximately 1 per 100,000 population per year, usually presents in adulthood, and affects men more often than women.

Richard K. Sterling – 29 August 2006

Corinne Castelnau, Frédéric Le Gal, Marie‐Pierre Ripault, Emmanuel Gordien, Michelle Martinot‐Peignoux, Nathalie Boyer, Bach‐Nga Pham, Sarah Maylin, Pierre Bedossa, Paul Dény, Patrick Marcellin, Elyanne Gault – 29 August 2006 – Hepatitis delta virus (HDV) can cause severe acute and chronic liver disease in patients infected by hepatitis B virus. Interferon alpha at high doses, although poorly efficient, is the only treatment reported to provide some benefit in chronic hepatitis delta. Pegylated interferon alpha (PEG‐IFN) has not yet been evaluated.

Heidi Barth, T. Jake Liang, Thomas F. Baumert – 29 August 2006 – With an estimated 170 million infected individuals, hepatitis C virus (HCV) has a major impact on public health. A vaccine protecting against HCV infection is not available, and current antiviral therapies are characterized by limited efficacy, high costs, and substantial side effects. Binding of the virus to the cell surface followed by viral entry is the first step in a cascade of interactions between virus and the target cell that is required for the initiation of infection.

Péter Fülöp, Zoltán Derdák, Anthony Sheets, Edmond Sabo, Eric P. Berthiaume, Murray B. Resnick, Jack R. Wands, György Paragh, György Baffy – 29 August 2006 – Fatty liver is vulnerable to conditions that challenge hepatocellular energy homeostasis. Lipid‐laden hepatocytes highly express uncoupling protein‐2 (UCP2), a mitochondrial carrier that competes with adenosine triphosphate (ATP) synthesis by mediating proton leak. However, evidence for a link between UCP2 expression and susceptibility of liver to acute injury is lacking.